Bevacizumab News and Research

RSS
Bevacizumab is a recombinant humanized monoclonal antibody directed against the vascular endothelial growth factor (VEGF), a pro-angiogenic cytokine. Bevacizumab binds to VEGF and inhibits VEGF receptor binding, thereby preventing the growth and maintenance of tumor blood vessels.
Ludwig scientists develop and test individualized ovarian cancer vaccine

Ludwig scientists develop and test individualized ovarian cancer vaccine

Vascular stabilization biomarker helps optimize timing of anticancer therapies

Vascular stabilization biomarker helps optimize timing of anticancer therapies

Treating metastatic breast cancer with immunotherapy

Treating metastatic breast cancer with immunotherapy

Study shows safety, efficacy of intravenous bevacizumab treatment for HHT related bleeding

Study shows safety, efficacy of intravenous bevacizumab treatment for HHT related bleeding

Scientists discover new target for anti-angiogenic tumor therapy

Scientists discover new target for anti-angiogenic tumor therapy

New first line combination therapy shows promising results in patients with advanced NSCLC

New first line combination therapy shows promising results in patients with advanced NSCLC

Study confirms safety and efficacy of new second line treatment for metastatic colorectal cancer

Study confirms safety and efficacy of new second line treatment for metastatic colorectal cancer

Genome-wide molecular tests can guide treatment in recurrent glioblastoma, study shows

Genome-wide molecular tests can guide treatment in recurrent glioblastoma, study shows

Risk factors, symptoms, diagnosis and treatment of ovarian cancer

Risk factors, symptoms, diagnosis and treatment of ovarian cancer

FDA grants approval for new biosimilar to treat multiple types of cancer

FDA grants approval for new biosimilar to treat multiple types of cancer

Combination immunotherapy as second or third line treatment of mesothelioma shows promising results

Combination immunotherapy as second or third line treatment of mesothelioma shows promising results

Tumor irradiation may prolong survival of NSCLC patients undergoing novel chemotherapy formulation

Tumor irradiation may prolong survival of NSCLC patients undergoing novel chemotherapy formulation

Study reveals radiation therapy advantage for patients with right-sided colorectal tumors

Study reveals radiation therapy advantage for patients with right-sided colorectal tumors

Two widely used drugs show effectiveness in treating patients with CRVO-associated macular edema

Two widely used drugs show effectiveness in treating patients with CRVO-associated macular edema

Molecular drug imaging likely to benefit children with brain tumors

Molecular drug imaging likely to benefit children with brain tumors

New biomarker helps better predict survival after surgical removal of colorectal metastases

New biomarker helps better predict survival after surgical removal of colorectal metastases

New techniques and treatments show promise for eliminating retinopathy of prematurity

New techniques and treatments show promise for eliminating retinopathy of prematurity

Combination treatment may be valuable therapeutic option for HER2-negative metastatic breast cancer

Combination treatment may be valuable therapeutic option for HER2-negative metastatic breast cancer

Researchers identify pathway that helps cancer cells to aggressively spread in the brain

Researchers identify pathway that helps cancer cells to aggressively spread in the brain

Allergan, Amgen submit BLA for ABP 215 oncology biosimilar medicine to FDA

Allergan, Amgen submit BLA for ABP 215 oncology biosimilar medicine to FDA